First of all merit attention multicentre randomized research with clear criteria of forming groups of patients (age, sex, diagnosis, disease duration, to the exclusion of evidence), designed to reliably confirm or refute the efficacy of ASCs in the treatment of various diseases. Many of these studies are conducted under the control of state institutions that allow the use of new methods treatment in their country, such as the administration to control food, Food and Drug Administration USA (FDA).
Widely used in koronar introduction of ASC in the first 24 hours after myocardial infarction. The results of treatment in analyzing early (6 months), and in the long-term (3 years) periods after transplantation.
In 2008, at the Medical Center Manila (Philippines) launched the first and second phases of clinical trials the use of autologous SVF cells in diabetes mellitus type 1 and 2. In 34 patients with type 1 diabetes in 3 months after intravenous injection of cells the decrease in blood glucose, glycosylated hemoglobin, triglycerides wasobserved.
Complications of cell therapy have been identified, and the positive effect with higher levels of C-peptide remained in half of the patients up to a 6 months follow-up. In the group of type 2 diabetes, this method wasalready used in several hundreds of patients.
The Veterans Medical Center in Washington (USA) is exploring the role of injecting lipoaspirata for treatment of diabetic wounds and ulcers of the lower extremities in venous insufficiency. The hospital in Toulouse (France) from 2009 to 2012 conducted clinical trial of intramuscular injection of ASCs in the critical lower limb ischemia. 20 patients were included in the treatment with stem cells of chronic ulcers of the soft tissues after radiotherapy. In 2009, Kanazawa University (Japan), studied the possibility of using ASCs to regenerate the liver cirrhosis.
Immunosuppressive properties of ASC were confirmed by many clinical examples of effective treatment of severe autoimmune diseases. The research showed reduction of symptoms of renal and hepatic failure, and the lack of side effects when observed from 13 to 40 months even in a patient with the re-introduction of cells.
Transplantation of ASC in patients with multiple sclerosis shows a prolonged positive trend due to remyelination of nerve fibers. Observed improvement over 3 months: reduction of spasticity of muscles, improvement of cognitive function, reduced neurological symptoms of cranial nerves after several weeks following the introduction of cells. Cellular technologies are used in cosmetics, in anti-ageing therapy. Thus, stem cells from adipose tissue due to its availability, security and reception, and differentiation potential of the unique immunological properties have become a new effective tool in many areas of regenerative medicine.
What they say about us
I am very very happy with all the care that I received and I recommend this treatment to anybody who want to give it a go. Come and have an open mind and meet these wonderful people who will treat you gently and with respect.
I’ll always be grateful. Thank you.continue
Well, the first month went well. I regained my psychophysical energy, especially in the sport I practice, I felt an improvement.
Now I hope, I hope that in the future, and the doctors tell me that it is better, I hope that in the future I'll feel all the better.continue
It's all been very nice, everybody has been very kind.
I don't think that anyone could fail to be impressed by the level of service and treatments and expertise everyone seems to have here, and, obviously, having medical treatment is not something that people want to have, but at the same time it's been as enjoyable as it could be to do that.continue
All form fields are required.